Lucira Health (LHDXQ) and Its Peers Critical Review
Lucira Health (LHDXQ) and Its Peers Critical Review
57.0% of Lucira Health shares are held by institutional investors. Comparatively, 46.6% of shares of all "Diagnostic substances" companies are held by institutional investors. 30.4% of Lucira Health shares are held by insiders. Comparatively, 14.1% of shares of all "Diagnostic substances" companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Lucira Health (NASDAQ:LHDXQ – Get Rating) is one of 41 public companies in the "Diagnostic substances" industry, but how does it contrast to its rivals? We will compare Lucira Health to related businesses based on the strength of its valuation, risk, analyst recommendations, profitability, dividends, earnings and institutional ownership.
Lucira Health（納斯達克股票代碼：LHDXQ — 獲取評級）是 “診斷物質” 行業的41家上市公司之一，但它與競爭對手相比有何不同？我們將根據Lucira Health的估值、風險、分析師建議、盈利能力、股息、收益和機構所有權的實力，將Lucira Health與相關業務進行比較。
Analyst Ratings
分析師評級
This is a breakdown of current ratings and price targets for Lucira Health and its rivals, as provided by MarketBeat.
這是MarketBeat提供的Lucira Health及其競爭對手目前的評級和目標價格的明細。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lucira Health | 0 | 0 | 0 | 0 | N/A |
| Lucira Health Competitors | 373 | 632 | 1237 | 19 | 2.40 |
| 賣出評級 | 保持收視率 | 買入評級 | 強勁的買入評級 | 評分分數 | |
| 露西拉健康 | 0 | 0 | 0 | 0 | 不適用 |
| 露西拉健康競爭對手 | 373 | 632 | 1237 | 19 | 2.40 |
As a group, "Diagnostic substances" companies have a potential upside of 38.58%. Given Lucira Health's rivals higher probable upside, analysts plainly believe Lucira Health has less favorable growth aspects than its rivals.
作爲一個整體，“診斷物質” 公司的潛在上漲空間爲38.58％。鑑於Lucira Health的競爭對手可能有更高的上行空間，分析師顯然認爲Lucira Health的增長方面不如競爭對手那麼有利。
Institutional & Insider Ownership
機構所有權和內部所有權
57.0% of Lucira Health shares are held by institutional investors. Comparatively, 46.6% of shares of all "Diagnostic substances" companies are held by institutional investors. 30.4% of Lucira Health shares are held by insiders. Comparatively, 14.1% of shares of all "Diagnostic substances" companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Lucira Health的57.0％股票由機構投資者持有。相比之下，所有 “診斷物質” 公司的46.6％的股份由機構投資者持有。Lucira Health的股份中有30.4％由內部人士持有。相比之下，所有 “診斷物質” 公司的14.1％的股份由內部人士持有。強大的機構所有權表明大型基金經理、對沖基金和捐贈機構認爲，從長遠來看，一家公司的表現將優於市場。
Earnings & Valuation
收益與估值
This table compares Lucira Health and its rivals gross revenue, earnings per share and valuation.
該表比較了Lucira Health及其競爭對手的總收入、每股收益和估值。
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Lucira Health | $93.06 million | -$64.83 million | -0.01 |
| Lucira Health Competitors | $472.03 million | $10.25 million | -53.53 |
| 總收入 | 淨收入 | 市盈率 | |
| 露西拉健康 | 9306 萬美元 | -6,483 萬美元 | -0.01 |
| 露西拉健康競爭對手 | 4.7203 億美元 | 1,025 萬美元 | -53.53 |
Lucira Health's rivals have higher revenue and earnings than Lucira Health. Lucira Health is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Lucira Health的競爭對手的收入和收益高於Lucira Health。Lucira Health的市盈率高於競爭對手，這表明它目前比該行業的其他公司更昂貴。
Risk and Volatility
風險和波動性
Lucira Health has a beta of 3.36, suggesting that its stock price is 236% more volatile than the S&P 500. Comparatively, Lucira Health's rivals have a beta of 1.36, suggesting that their average stock price is 36% more volatile than the S&P 500.
Lucira Health的beta值爲3.36，這表明其股價的波動性比標準普爾500指數高236％。相比之下，Lucira Health的競爭對手的beta值爲1.36，這表明他們的平均股價的波動性比標準普爾500指數高36％。
Profitability
盈利能力
This table compares Lucira Health and its rivals' net margins, return on equity and return on assets.
該表比較了Lucira Health及其競爭對手的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| Lucira Health | -67.54% | -13.55% | -8.47% |
| Lucira Health Competitors | -802.63% | -114.55% | -27.76% |
| 淨利潤 | 股本回報率 | 資產回報率 | |
| 露西拉健康 | -67.54% | -13.55% | -8.47% |
| 露西拉健康競爭對手 | -802.63% | -114.55% | -27.76% |
Summary
摘要
Lucira Health beats its rivals on 7 of the 10 factors compared.
在比較的10個因素中，Lucira Health在7個因素上擊敗了競爭對手。
About Lucira Health
關於 Lucira Health
(Get Rating)
（獲取評分）
Lucira Health Inc. is a medical technology company. It is focused on the development and commercialization of transformative and infectious disease test kits. Lucira Health Inc. is based in Emeryville, California.
Lucira Health Inc. 是一家醫療技術公司。它專注於變革性和傳染病檢測試劑盒的開發和商業化。Lucira Health Inc. 總部位於加利福尼亞州的埃默裏維爾。
Receive News & Ratings for Lucira Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucira Health and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Lucira Health Daily 的新聞和評級 -在下面輸入您的電子郵件地址，即可通過Marketbeat.com的免費每日電子郵件時事通訊接收Lucira Health及相關公司的最新新聞和分析師評級的簡明每日摘要。
